Abolishing Drug Rebates May Push Consumer Drug Costs Higher

The Trump Administration has repeatedly said that controlling high drug prices is a top priority, and earlier this year it released a fifty-point plan for accomplishing this. In the last few weeks it has taken steps to fulfill one of those points, namely its pledge to curtail the role of Pharmacy Benefit Managers (PBMs) in negotiating rebates for the purchasers they serve, including employers, unions, and government programs.